Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte-associated protein 4 therapy: A retrospective cohort study - Sheida Naderi-Azad, BSc; Faisal Sickandar, MD; Rossanna C. Pezo, MD, PhD, FRCP (Elsevier, 2021)